telisotuzumab vedotin-tllv (Emrelis)
telisotuzumab vedotin-tllv is an FDA-licensed reference biologic from AbbVie Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2025
Reference approved
Reference product
Emrelis telisotuzumab vedotin-tllv
AbbVie Inc.
- Approved
- May 14, 2025
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for telisotuzumab vedotin-tllv, in chronological order.
Reference approval
Approval date of the reference telisotuzumab vedotin-tllv product.
1 yr 1 mo ago
Frequently asked questions
Are there biosimilars approved for telisotuzumab vedotin-tllv (Emrelis)?
No 351(k) biosimilars or interchangeable biosimilars referencing telisotuzumab vedotin-tllv are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.